GW Pharma operates two grow facilities in secret locations in England that produce 20 tons annually of a strain of cannabis specifically for the CBD.
Quite a bit of biomass.
It's obvious Guy and the now deceased Whittle possessed a rare combination of not only having a head for science but also a head for business.
And I think that is one key factor in the vote of confidence institutional investors have given to this company. 6 or 7 high level analysts cover the stock. Institutions own 70 percent of outstanding 27.7 million shares.
You read that correctly. And that is after two secondary offerings.
Market Data 
Markets 
AI
